New Haven-based biotech company Cybrexa Therapeutics announced recently that its first in-human study of its oncology drug candidate showed evidence of effectiveness against tumors.
The data also showed the drug was safe and well tolerated, according to the clinical stage oncology company, which was founded in 2017.
Cybrexa is developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics.
On Oct. 28, the company presented its study findings at an industry meeting in Spain, the annual EORTC-NCI-AACR (ENA) Symposium.
The human study evaluated Cybrexa’s drug candidate, CBX-12, in patients with advanced or metastatic solid tumors.
The principal investigator, Dr. Funda Meric-Bernstam, is chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
According to Meric-Bernstam, researchers saw anti-tumor activity in multiple tumor types.
“In this Phase I study, CBX-12 demonstrated safety and tolerability, without significant gastrointestinal toxicity,” Meric-Bernstam said.
Patients involved in the trial were treated with escalating doses of CBX-12.
The ongoing study continues to evaluate safety and tolerability. The data collected will be used for determining dosage in a Phase II study.
Dr. Arthur DeCillis, Cybrexa’s chief medical officer, said of the recent results, “This study’s data provides us with important early signs of clinical viability of Cybrexa’s alphalex technology platform, which opens the door for us to move forward rapidly with the development of our pipeline.”
Cybrexa’s pipeline aims to combat breast, ovarian, non-small-cell lung cancer and a range of other tumors.
Contact Michelle Tuccitto Sullo at msullo@newhavenbiz.com.
